Evaluation of Four Rapid Tests for Detection of Hepatitis B Surface Antigen in Ivory Coast.

BACKGROUND: Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. Hepatitis B surface antigen (HBsAg) rapid diagnostic tests (RDTs) could be an ideal tool for a large-scale HBV screening in settings with high endemicity but limited infrastructure. The aim of this study was to evaluate the diagnosis performance of such RDTs for screening HBV infection in Ivory Coast. METHODS: From September 2018 to January 2019, a cross-sectional phase I evaluation study of RDTs was conducted in three laboratories of Abidjan (CeDReS, CNTS and IPCI), on a panel of 405 whole blood samples and 699 plasmas. Four HBsAg RDTs (Determine™ HBsAg, SD Bioline HBsAg WB®, Standard Q HBsAg® and Vikia HBsAg®) were evaluated. The diagnostic performance (sensitivity and specificity) was calculated in comparison to the reference sequential algorithms of two EIA tests (Dia.Pro HBsAg® one version ULTRA and Monolisa™ HBsAg ULTRA). RESULTS: The Determine™ HBsAg and Vikia HBsAg® tests performed well, with 100% of sensitivity, specificity both on plasma and on whole blood. For SD Bioline HBsAg WB® and Standard Q HBsAg®, the specificities were 99.8% and the sensitivities 99.3% and 97.1% respectively. Finally, there were a total of 19 false negative results: 3 with SD Bioline HBsAg WB® and 16 with Standard Q HBsAg®. CONCLUSION: Determine HBsAg® from Alere and Vikia HBsAg® from Biomérieux are the most suitable RDTs for screening for HBV in Ivory Coast. A phase II evaluation must be initiated.

Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.

OBJECTIVE: This work aims to evaluate the therapeutic survey of adverse events during antiviral treatment of hepatitis in the three major University Hospitals in Abidjan. MATERIALS AND METHODS: A retrospective cross-sectional descriptive study of 203 patients from August 1, 2015, to July 31, 2018, enumerated adverse events during antiviral treatments, drugs used for their management, and their clinical or biological impact. RESULTS: The following was seen: hematological disorders during treatment with pegylated interferon α-2a (88.61%) and ribavirin (77.55%), pain syndrome when using pegylated interferon α-2a (90.5%), and digestive disorders while taking sofosbuvir (60.71%) and daclatasvir (66.67%). Hematological disorders were managed with filgrastim for neutropenia and oral iron or blood transfusion for anemia and/or thrombocytopenia. Pain syndrome was treated with paracetamol. As for digestive disorders, they were most often managed with activated charcoal. CONCLUSION: Correction of the adverse events was made either using causal treatment or using symptomatic drugs. However, some drugs, in particular hematopoietic factors, have been less used due to their costs.

Changes in viral hepatitis B screening practices over time in West African HIV clinics.

BACKGROUND: We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa. METHODS: A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression. RESULTS: A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01-1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09-3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% confidence interval: 15.5-24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen. CONCLUSION: Hepatitis B screening among HIV-infected patients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.

Quelle strategie de depistage et de prise en charge des hepatites virales en entreprise ?

Introduction. Les hepatites virales posent un veritable probleme de sante publique en Cote d'ivoire. Le but de ce travail etait de rapporter la strategie de depistage et de prise en charge des hepatites virales au sein d'une entreprise financiere de la Cote d'Ivoire. Methodes. Il s'agissait d'une etude transversale qui s'est deroulee selon un chronogramme en trois phases du 18 aout 2014 au 12 septembre 2014 au sein des differentes agences de l'entreprise. La campagne de depistage avait ete precedee d'une conference de sensibilisation des agents de l'entreprise. Les marqueurs de depistage etaient l'Ag HBs et les AC anti HBc totaux pour l'hepatite B et l'Ac anti VHC pour l'hepatite C. Les patients dont les Ac anti VHC etaient positifs avaient eu un dosage de l'ARN viral C. Les travailleurs qui avaient deja ete vaccines; sans avoir ete depistes et qui apres depistage n'etaient pas porteurs les marqueurs de l'hepatite B positifs avaient eu un dosage quantitatif de l'Ac anti HBs. La serologie retrovirale; de meme que les anticorps anti VHD totaux avaient ete systematiquement recherches chez les travailleurs dont l'antigene HBs etaient positifs. De meme tous ceux qui etaient porteurs de l'ARN viral C ont ete systematiquement depistes pour le VIH. Les parametres d'etude etaient : le taux de participation; la prevalence de l'antigene HBs; la prevalence des Ac anti VHC; le nombre d'agents eligibles a la vaccination; le nombre de patients eligibles a un traitement anti viral; le nombre de patients non eligibles a un traitement mais sous surveillance. Resultats. 1025 agents sur un effectif de 1137 avaient participe a la campagne de depistage soit un taux de participation de 90;14%. La prevalence des marqueurs de l'hepatite B et C etaient respectivement de 6;34% et de 1;46%. Sur 80 personnes depistees positives a l'hepatite B et C; seules 67 ont ete prises en charge (83;75%) les 11 autres (16;25%) n'avaient pas repondu a la convocation du medecin. 224 agents avaient ete proposes pour la vaccination. La mise en route du traitement antiviral B avait concerne 07 patients soit 12;96% des patients porteurs de l'hepatite B et 01 seul patient pour l'hepatite C. Conclusion. La strategie de lutte contre les hepatites virales au sein de cette entreprise a ete favorablement accueillie par les travailleurs de celle -ci; avec un taux de participation de 90;14% pour le depistage. La prevalence de l'hepatite B reste elevee (6;34%). Un plaidoyer pour une meilleure accessibilite au Tenofovir et aux DASS merite d'etre fait

[Hepatitis B: cross-sectional study of knowledge and immunization among students at University of Cocody, Ivory Coast]. / Connaissance et couverture vaccinale contre l'hépatite virale B (HVB) : étude transversale parmi les étudiants de l'université de Cocody, Côte d'Ivoire.

BACKGROUND: To evaluate knowledge about hepatitis B and vaccination coverage among students at Cocody's University, Ivory Coast. MATERIALS AND METHODS: A cross-sectional study was conducted during the academic year 2005-2006 (2557 students). Parameters were collected by interview using a survey chart. Factors influencing knowledge and vaccination against hepatitis B were analyzed by logistic regression. RESULTS: The majority of students (n=1174, 69.4% [95% CI 68-71]) knew about hepatitis B. Only 17.5% and 26.1% of students respectively were aware of sexual and blood transmission. None of the students were aware of maternal-fetal transmission. Factors associated with knowledge of hepatitis B were enrollment in health sciences (Odds Ratio=24.19 [95% CI 8.65-76.63]) and having a scholarship (Odds Ratio=2.34 [95% CI 1.54-3.56]). Vaccination coverage against hepatitis B was low (Odds Ratio=3.7% [95% CI 3-4]). Factors associated with vaccination were: knowledge of hepatitis B (Odds Ratio=6.83 [95% CI 4.57-10.27]), enrollment in health sciences (Odds Ratio=3.59 [95% CI 2.60-4.96]), marriage (Odds Ratio=2.04 [95% CI 1.13-3.64]) and having a scholarship (Odds Ratio=1.60 [95% CI 1.09-2.35]). CONCLUSION: Knowledge and vaccination coverage against hepatitis B among students at Cocody's University is low. Students should be given information about hepatitis B and access to free vaccination. Students enrolled in health sciences should be vaccinated before admission because of specific risks of contamination, for themselves and for their patients.

[Hepatitis B knowledge among secondary school students in Côte d'Ivoire]. / Connaissance de l'hépatite virale B par les élèves des écoles secondaires en Côte d'Ivoire.

AIM: The purpose of this study was to assess hepatitis B knowledge among secondary school students' in Côte d'Ivoire in order to promote the inclusion of hepatitis B education in school curricula. MATERIAL AND METHODS: a single cross-sectional survey involving six schools (7,376 students) was conducted. Data were collected using a self-administered questionnaire. RESULTS: All students present on the day of the survey agreed to participate in the study (100%, n = 3,352). The mean age of the participants was 17.9 years (10-26 years), with a male-to-female sex ratio of 1.68. Among them, 2,552 (76.6%) had heard of the HVB. School was the main source of information (12%), after the mass media (62%). The causative agent of the disease was known by 74.1% of students (n = 2,484), sexual transmission by 39.3% (n = 1316), and blood-borne transmission by 57.2% (n = 1919). Respectively 29%, 40% and 41% of the students were aware that acupuncture, body piercing and tattooing are high-risk practices. Only 35.7% of the students knew that there was an effective vaccine. The factors associated with hepatitis B knowledge were: being aged 16 to 20 years (OR = 1.73 [95% CI 1.198 to 2.49]), living in a permanent house or apartment (OR = 1.58 [95% CI 1.234 to 2.02]) or in a house or apartment with no more than 2 persons per room (OR = 1.41 [95% CI 1.15 to 1.74]), being in terminale (final year of high school) (OR = 2.54 [2.01 to 3, 20IC95%]), and having two working parents (OR =1.54 [95% CI 1.25 to 1.88]). CONCLUSION: The students' knowledge of the hepatitis B virus was found to be inadequate and superficial. Early awareness programs provided as part of the official curriculum and measures to improve the social conditions of students should help to improve knowledge in this area.

Usefulness of Noninvasive Predictors of Oesophageal Varices in Black African Cirrhotic Patients in Côte d'Ivoire (West Africa).

Aims. To determine the usefulness of platelet count (PC), spleen diameter (SD) and platelet count/spleen diameter ratio (PC/SD ratio) for the prediction of oesophageal varices (OV) and large OV in black African patients with cirrhosis in Côte d'Ivoire. Materials and Methods. Study was conducted in a training sample (111 patients) and in a validation sample (91 patients). Results. Factors predicting OV were sex: (OR = 0.08, P = 0.0003), PC (OR = 12.4, P = 0.0003), SD (OR = 1.04, P = 0.002) in the training sample. The AUROCs (±SE) of the model (cutoff ≥ 0.6), PC (cutoff < 110500), SD (cutoff > 140) and PC/SD ratio (cutoff ≤ 868) were, respectively; 0.879 ± 0.04, 0.768 ± 0.06, 0.679 ± 0.06, 0.793 ± 0.06. For the prediction of large OV, the model's AUROC (0.850 ± 0.05) was superior to that of PC (0.688 ± 0.06), SD (0.732 ± 0.05) and PC/SD ratio (0.752 ± 0.06). In the validation sample, with PC, PC/SD ratio and the model, upper digestive endoscopy could be obviated respectively in 45.1, 45.1, and 44% of cirrhotic patients. Prophylactic treatment with beta blockers could be started undoubtedly respectively in 36.3, 41.8 and 28.6% of them as having large OV. Conclusion. Non-invasive means could be used to monitor cirrhotic patients and consider treatment in African regions lacking endoscopic facilities.

[Diagnosis of hematochezia in Abidjan Cocody University Hospital (Ivory Coast)]. / Diagnostic des rectorragies au centre hospitalier universitaire de Cocody à Abidjan (Côte d'Ivoire)

AIM: To determine the prevalence of endoscopic lesions, according to age and location, in patients with rectal bleeding who underwent total colonoscopy. METHODS: Retrospective observational study examining records from the hepatogastroenterology department at the Cocody University Hospital (Abidjan) of colonoscopies for rectal examination from September 1, 1991, through August 15, 2007. The data collected and analyzed from the records included age, sex and colonoscopy results. A p value less than 0.05 was considered statistically significant. RESULTS: Of 1,158 colonoscopies, 270 (23.3%) were performed for hematochezia: 105 women (mean age: 48.8 years ± 19.9 years, range: 10-96 years) and 165 men (mean age: 46 ± 14.2, range: 21-83 years) with a sex-ratio (M/F) of 1.57. Because colorectal cancer seems to occur at a younger age in Africa, patients were divided into two groups (aged 45 years: 139 [51.5%] and above 45 years: 131 [48.5%]). The abnormalities found were consistent with anal pathologies (16.3%), polyps (10.4%), diverticular disease (11.1%), colorectal inflammatory lesions (21.5%) and carcinoma (7%). Diverticula were significantly more common in those older than 45 years and inflammatory lesions in the younger group (p < 10(-3)). More than two thirds of the significant lesions were found in the distal colon (p < 10(-3)). CONCLUSION: The predominance of distal colon lesions suggests that exploration by flexible sigmoidoscopy can be performed in patients with low to moderate risk of colorectal cancer, with total colonoscopy reserved for the population at high risk.